Column: This is how the Danish Medicines Council should strengthen its application process

Roche and Novartis have been behind almost 10 percent of all application submissions to the Danish Medicines Council since 2017. In a column, representatives from both firms point out three problems and make concrete proposals for how to improve the council’s work.

In 2021, the Danish Medicines Council processed 50 new drug applications. Unfortunately, the established allotted case processing time of 84 days was exceeded with every application. This is the fifth year in a row that case processing got behind schedule, according to the council’s latest year-in-review.

This is not sustainable for the patients, the healthcare system or the companies. That’s why it’s good that the Danish Medicines Council has stated it welcomes proposals for how to improve. We would like to acknowledge this.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs